Want to see HK:0897 full AI Analyst Report?
0897 Stock Chart & Stats
HK$0.36
>-HK$0.01(-1.67%)
At close: 4:00 PM EST
HK$0.36
>-HK$0.01(-1.67%)
Day’s Range― - ―
52-Week RangeHK$0.27 - HK$0.51
Previous CloseN/A
Volume490.00K
Average Volume (3M)632.59K
Market Cap
HK$334.31M
Enterprise ValueHK$560.58
Total Cash (Recent Filing)HK$147.44M
Total Debt (Recent Filing)HK$279.29M
Price to Earnings (P/E)88.9
Beta0.38
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.5%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,114,382,900
10 Day Avg. Volume746,291
30 Day Avg. Volume632,591
Financial Highlights & Ratios
PEG Ratio-2.14
Price to Book (P/B)0.31
Price to Sales (P/S)0.54
P/FCF Ratio6.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet DeleveragingSharp deleveraging materially reduces financial risk and refinancing pressure. A much lower debt load and debt/equity ratio give management flexibility to reallocate cash to operations, working capital or targeted investments, improving resilience across economic cycles.
Positive Cash GenerationConsistent positive operating and free cash flow provide internal funding for day-to-day operations, capex and debt service without reliance on external capital. This persistent cash generation supports continued deleveraging and creates optionality for strategic investments over the medium term.
High Gross Margin & EBITDAAn improved gross margin and positive EBITDA indicate durable product-level economics and likely pricing or mix advantages. Strong gross margins help absorb SG&A, enable targeted reinvestment in retail/distribution, and form a foundation for returning to consistent operating profitability.
Bears Say
Multi-year Revenue DeclineSustained top-line contraction reduces scale, weakens operating leverage, and limits the company’s ability to fund store operations or expand channels. Persistent revenue decline undermines long-term growth prospects and makes recovery of operating margins more difficult without structural changes.
Thin Net Margins & Negative Operating ProfitVery low net margins and continued negative operating profit despite EBITDA positivity point to structural cost pressure below gross profit (e.g., SG&A or distribution). This constrains return on equity, limits reinvestment capacity, and hinders sustainable earnings improvement.
Weakened And Volatile Free Cash FlowA large year-over-year FCF drop and historical volatility reduce the firm’s financial cushion for shocks and strategic investments. Even with lower debt, declining and inconsistent cash conversion increases sensitivity to revenue swings and complicates medium-term planning.
Wai Yuen Tong Medicine Holdings Limited News
0897 FAQ
What was Wai Yuen Tong Medicine Holdings Limited’s price range in the past 12 months?
Wai Yuen Tong Medicine Holdings Limited lowest stock price was HK$0.27 and its highest was HK$0.51 in the past 12 months.
What is Wai Yuen Tong Medicine Holdings Limited’s market cap?
Wai Yuen Tong Medicine Holdings Limited’s market cap is HK$334.31M.
When is Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date?
Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date is Dec 01, 2026 which is in 122 days.
How were Wai Yuen Tong Medicine Holdings Limited’s earnings last quarter?
Wai Yuen Tong Medicine Holdings Limited released its earnings results on Jun 25, 2026. The company reported HK$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.001.
Is Wai Yuen Tong Medicine Holdings Limited overvalued?
According to Wall Street analysts Wai Yuen Tong Medicine Holdings Limited’s price is currently Overvalued.
Does Wai Yuen Tong Medicine Holdings Limited pay dividends?
Wai Yuen Tong Medicine Holdings Limited pays a Notavailable dividend of HK$0.03 which represents an annual dividend yield of 7.5%. See more information on Wai Yuen Tong Medicine Holdings Limited dividends here
What is Wai Yuen Tong Medicine Holdings Limited’s EPS estimate?
Wai Yuen Tong Medicine Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wai Yuen Tong Medicine Holdings Limited have?
Wai Yuen Tong Medicine Holdings Limited has 1,114,382,900 shares outstanding.
What happened to Wai Yuen Tong Medicine Holdings Limited’s price movement after its last earnings report?
Wai Yuen Tong Medicine Holdings Limited reported an EPS of HK$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Wai Yuen Tong Medicine Holdings Limited?
Currently, no hedge funds are holding shares in HK:0897
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wai Yuen Tong Medicine Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.26%
Trailing 12-Months
Company Description
Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited operates as an investment holding company with a multifaceted business portfolio. Its core activities encompass the production, processing, and retail distribution of traditional Chinese medicines, Western pharmaceuticals, and a range of health and personal care products. These offerings reach customers across Hong Kong, mainland China, Macau, and international markets. The company's Chinese medicine and health food lines are marketed under the Wai Yuen Tong brand, while its Western pharmaceutical and personal care items are available under the Madame Pearl's and Pearl's labels. Beyond its product-focused segments, the group also engages in property investment, ownership, and sales, provides financial services, and oversees an agricultural produce exchange. As of March 31, 2022, Wai Yuen Tong maintained 63 retail stores in Hong Kong. Founded in 1897, the company is headquartered in Kowloon Bay, Hong Kong, and operates as a subsidiary of Rich Time Strategy Limited.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―